EU Clinical Trial Information System (CTIS)

Brand Logo

Brand Logo Light

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

I searched for some studies on AstraZeneca Clinical Trials, and found these studies that may also be of interest to you.
Here is the link to my search results

Official Title

This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium

Study to describe treatment patterns and outcomes in EGFRm NSCLC patients in Belgium

NCT ID

Patient Level Data

Therapeutic Area

chemotherapy, EGFR TKI, immunotherapy, other

Chemotherapy, EGFR TKI, immunotherapy, other

Research Site

REtrospective, obserVational study to describe the treatment patterns and outcomes of Epidermal Growth Factor receptor mutant (EGFRm) locally Advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) patients in Belgium

observation window: 
between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Descriptive statitistics will be used to analyse these endpoints.

observation window:
between date of diagnosis until the data cut-off, 1 september 2018, end of clinical activity or death, whichever comes first. Descriptive statistics will be used to analyse these endpoints.

observation window:
between date of diagnosis until the data cut-off, 01 September 2018 until end of clinical activity or death, whichever comes first. Descriptive statistics will be used to analyse these endpoints.

observation window: 
between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first.  Kaplan-Meier analysis will be used.

observation window: 
between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Kaplan-Meier analysis will be used.

OS will be measured overall for all EGFRm NSCLC patients and depending on receipt of Osimertinib treatment and line of Osimertinib treatment.
observation window: 
between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. 
Kaplan-Meier analysis will be used.

Study to describe treatment patterns and outcomes in EGFRm NSCLC patients in Belgium - REVEAL

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D5161R00007&attachmentIdentifier=872df4e2-12ee-4617-83cd-e34e9d2877b3&fileName=REVEAL_Clinical_Study_Report_redacted_synopsis_(26_Feb_2020).pdf&versionIdentifier=

Trial Results Summaries

Contacts

Contact

Study to describe treatment patterns and outcomes in EGFRm NSCLC patients in Belgium - REVEAL

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5161R00007&amp;attachmentIdentifier=872df4e2-12ee-4617-83cd-e34e9d2877b3&amp;fileName=REVEAL_Clinical_Study_Report_redacted_synopsis_(26_Feb_2020).pdf&amp;versionIdentifier=

Trial Results Summaries

Contacts

Contact

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D5161R00007&attachmentIdentifier=872df4e2-12ee-4617-83cd-e34e9d2877b3&fileName=REVEAL_Clinical_Study_Report_redacted_synopsis_(26_Feb_2020).pdf&versionIdentifier=